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ABSTRACT: The cyclization of N-alkenylamides catalyzed by iodoarenes under oxidative conditions is presented. Five-, six- and 
seven-membered rings with a range of substitutions can be prepared by this route. Preliminary data from the use of chiral iodoarenes 
as precatalysts show that enantiocontrol is feasible. 
Research in hypervalent iodine chemistry has gained consid-
erable momentum in recent years.1 In particular, the emergence 
of catalytic and enantioselective processes with iodine(III) spe-
cies is starting to make these competitive with metal-catalysis.2 
Recent examples include the catalytic enantioselective spirolac-
tonization of phenols,3 dioxygenation of styrenes,4 and intramo-
lecular C-H/C-H cross-coupling.5 This ability to effect “metal-
like” synthetic transformations without the toxicity, supply or 
cost issues of transition metal salts is attractive. 
We have previously developed catalytic methods using in-
situ generated hypervalent iodine species and have reported the 
oxidative cyclization of δ-alkynyl β-ketoesters6 and the enanti-
oselective oxidative cyclization of δ-ketoacids.7 We wished to 
extend this catalytic concept to the formation of useful hetero-
cycles such as oxazolines and dihydrooxazines. Oxazolines are 
common structural motifs found in natural products with nota-
ble biological activities, e.g. the leupyrrins, active against fungi 
and eukaryotic cells,8 and the bistratamides, which possess an-
ticancer properties (Figure 1).9 Dihydrooxazines are useful syn-
thetic intermediates in organic synthesis10 and derivatives pos-
sessing fungicidal activity have also been reported.11 
In this Communication, we disclose our results on the cata-
lytic cyclization of unsaturated amides to give oxazolines, di-
hydrooxazines and larger ring analogs. At the beginning of our 
study, Moon and Harned published the stoichiometric hyperva-
lent iodine mediated cyclization of N-allylamides (Scheme 1).12 
Their report was limited to five membered ring formation, the 
use of terminal alkenes and the products described were all ra-
cemic. Herein, we reveal catalytic conditions for the cyclization 
and expand the scope of the process to include other ring sizes 
and more substituted alkenes. In addition, we have achieved en-
antiocontrol in this cyclization using chiral iodoarenes.  
  
Figure 1. Examples of natural products containing oxazolines. 
There are few examples in the literature of iodoarene-cata-
lyzed reactions involving alkenes.4,13 One issue with these pro-
cesses is the potential for undesired oxidation of the olefin in 
preference to the iodoarene especially as common oxidants for 
the conversion of iodoarenes into the active iodine(III) species 
include peracids.  
 
 
 
 
 
 
  
Scheme 1. Cyclization of N-alkenylamides by iodine(III) spe-
cies. 
 
We began our investigation with N-allylbenzamide 1a and 
used reaction conditions similar to that used by us in previous 
reports, namely iodobenzene as the precatalyst with an oxidant, 
m-CPBA, an acid, TFA, and a solvent, acetonitrile, at room tem-
perature (Table 1, entry 1). Unfortunately, these conditions led 
to no conversion of the starting material; not even epoxidation 
of the alkene occurred. However, changing the oxidant to Se-
lectfluor led to a small amount of the desired product 2a being 
formed (entry 2). Importantly, a basic workup of the reaction 
mixture was required in order to isolate the product. Changing 
the iodoarene catalyst led to surprising variations in yield: 2-
iodoanisole led to a 62% yield (entry 3), whereas 3-iodoanisole, 
4-iodoanisole and 5-iodo-m-xylene provided low yields of isox-
azoline (entries 4, 5 and 6). We have demonstrated previously 
that the presence of a 2-methoxy substituent stabilizes arylio-
dine(III) species.14 Guilbault and Legault demonstrated that the 
steric hindrance caused by the introduction of a methyl group 
ortho to the iodine atom in iodoarene precatalysts led to drastic 
rate enhancements in the α-tosyloxylation of ketones.15 Using 
2-iodoanisole as catalyst, the oxidant was varied, however the 
use of m-CPBA and Oxone both led to no conversion (entries 7 
and 8). Finally, running the reaction without the 2-iodoanisole, 
but with the Selectfluor, led to complete recovery of the starting 
amide showing that the iodoarene is necessary for this process 
to proceed (entry 9).  
With the optimized cyclization reaction conditions in hand, 
we next studied the scope of this process (Scheme 2). A variety 
of arylamides were successfully cyclized including electron 
rich and electron poor examples to provide the corresponding 
oxazolidinones 2a-2e in good yields. Subjecting acetamide 1f  
to the reaction conditions led to a mixture of products and 2f 
could not be isolated in pure form. Furan oxazoline 2g was iso-
lated in 79% yield and 2h was isolated as a ~1:1 mixture of di-
astereomers in 74% combined yield. The cyclization of amides 
1i-1m was investigated next and we were pleased to find that 
the six membered rings 2i-2m formed in good yields. However, 
two equivalents of Selectfluor were generally required for com-
plete conversion to occur in these cases. In addition, the seven 
membered ring 2n was successfully formed in 30% yield. How-
ever, the eight membered ring 2o was not formed. In theory, 2n 
or 2o could cyclize to the corresponding pyrrolidine or piperi-
dine but neither of these was observed. 
Table 1. Investigation of reaction conditions 
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a
 Yields of isolated compounds. Selectfluor: 1-chloromethyl-4-
fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate). 
Scheme 2. Scope of cyclization of mono-substituted alkenes 
  
With a desire to increase the scope of the cyclization further, 
1,1-disubstituted alkenes 1p and 1q were subjected to the reac-
tion conditions (Scheme 3). Methyl derivative 2p was formed 
in 81% yield whereas the phenyl derivative 2q was not isolated. 
In the latter case, complete conversion of the starting material 
was observed but several unidentified products were formed 
  
which could not be separated. Cis-1,2-Disubstituted alkene 1r 
cyclized to the bicycle 2r in 56% yield as one diastereomer. No 
sign of the other diastereomer was detectable by NMR analysis 
of the crude reaction mixture. Attempts to cyclize a trisubsti-
tuted alkene were unsuccessful as undesired background alkene 
addition processes occurred. 
Scheme 3. Scope of cyclization of di-substituted alkenes 
 
The mechanism of this cyclization is proposed to involve ox-
idation of the iodoarene to the iodine(III) species which acti-
vates the alkene to intramolecular attack by the amide oxygen 
to generate intermediate 3 (Scheme 4). Nucleophilic addition of 
TFA, or its conjugate base, breaks the alkyl carbon-iodine bond 
in 3, which regenerates the iodoarene catalyst and releases the 
cyclized product 4. This compound 4 cannot be isolated as it is 
unstable, but it is believed to be the trifluoroacetate. Nonethe-
less, treatment of this with 2 M NaOH solution provides the sta-
ble alcohol 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Postulated cyclization reaction mechanism 
 
With an effective cyclization process in hand, we turned our 
attention to the use of chiral iodoarene precatalysts 6-10 in order 
to develop an enantioselective version of this process.16 Using 
bisdimethylamide precatalyst 6 a very good yield of 2i was ob-
tained with moderate enantioselectivity of 82:18 er (Table 2, 
entry 1). Interestingly, the amount of precatalyst could be low-
ered to 10 mol % without a drop in yield, compared to the use 
of 2-iodoanisole. To determine the effect of temperature on the 
cyclization, the reaction was repeated at 50 oC and at -10 oC, 
however selectivity was lower in the former case and about the 
same in the latter (entries 2 and 3). Conducting the reaction with 
bistrifluoromethanesulfonamide instead of TFA led to lover 
yield and lower selectivity (entry 4). Using methanol as solvent 
instead of acetonitrile led to formation of methyl ether 5 in place 
of alcohol 2i, but in low yield and with 63:37 er (entry 5). Using 
a 1:1 or 2:1 acetonitrile/methanol mixture as solvent led to sep-
arable mixtures of 2i and 5 being formed (entries 6 and 7). The 
enantiomeric ratio of ether 5 was up to 81:19, equalling the 
highest obtained for 2i. We then screened a few other related 
precatalysts 7-10 but did not see superior selectivity. With 
diisopropylamide precatalyst 7, the conversion in MeCN was 
very low, however changing to a 1:2 mixture of MeCN and 
MeOH led to complete conversion to ether 6 with 75:25 er (en-
try 9). Mesityl amide 8 and ethers 9 and 10 led to moderate 
yields and enantioselectivites (entries 10-12). However, with 
the t-butyl ester precatalyst 10 the major enantiomers of prod-
ucts formed were opposite to the other precatalysts (entry 12). 
 
 
 
 
 
  
Table 2. Preliminary chiral precatalyst screening 
 
a
 Yields of isolated compounds. b Determined by chiral HPLC 
analysis. c Reaction performed at 50 oC. d Reaction performed at -
10 oC. e Bistrifluoromethanesulfonamide used instead of TFA. 
Cyclization of amide 1a to generate isoxazoline 2a was also 
performed using chiral precatalyst 7 and the product was gen-
erated in 84.5:15.5 er (Scheme 5).  
 
Scheme 5. Enantioselective formation of isoxazoline 2a 
 
In conclusion, the cyclization of unsaturated amides using 
catalytic quantities of iodoarenes has been developed. 2-Io-
doanisole has proven to be a superior precatalyst than other io-
doarenes tested in this process. In addition, chiral iodoarenes 
have been utilized to impart enantioselectivity, and levels of 
control up to 81:19 er have been achieved so far. Further work 
on related cyclizations, and efforts to improve observed enanti-
oselectivities, is underway and will be reported in due course. 
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